Recent Company News

• 04:02 PM ET Dec 18, 2025
  

  Galapagos announces topline results from two Phase 3-Enabling studies with selective TYK2 inhibitor GLPG3667 in dermatomyositis and systemic lupus erythematosus (€26.96, 0.00)

• 01:32 AM ET Dec 08, 2025
  

  Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025; remains focused on the intention to wind down the cell therapy activities (€27.04, 0.00)

• 11:38 AM ET Nov 25, 2025
  

  Galapagos initiated market perform at Bernstein (€26.86, 0.00)

• 09:28 AM ET Nov 19, 2025
  

  Transcript Intelligence: Galapagos at Jefferies Global Healthcare Conference (€26.72, +0.56)

• 11:03 AM ET Nov 06, 2025
  

  Transcript Intelligence: Galapagos Q3 Earnings Guidance (€26.90, +0.80)

• 11:03 AM ET Nov 06, 2025
  

  Transcript Intelligence: Galapagos Q3 Earnings Themes (€26.90, +0.80)

• 11:03 AM ET Nov 06, 2025
  

  Transcript Intelligence: Galapagos Q3 Earnings Q&A (€26.90, +0.80)

• 04:45 PM ET Nov 05, 2025
  

  Galapagos reports 9M EPS (€7.00) vs year-ago €0.70 (€26.10, 0.00)

• 04:29 PM ET Oct 23, 2025
  

  Galapagos to present In Vitro Data at ACR Convergence 2025 on GLPG3667 vs other TYK2 Inhibitors (€27.78, 0.00)

• 05:04 PM ET Oct 22, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market